

Cadila Healthcare Limited

Registered Office: Zydus Tower, Satellite Cross Roads, Ahmedabad - 380015 Tel. No.: (+91-79) 2686 8100 Fax No.: (+91-79) 2686 2365/66 Website: www.zyduscadila.com

CIN: L24230GJ1995PLC025878

PART I

Statement of Results for the Quarter Ended 30/06/2014

Statement of Results for the Quarter Ended 30/06/2014												
Rupees in Lacs							Rupees in Lacs					
CONSOLIDATED							COMPANY					
		Corresponding 3 months							Corresponding 3 months			
		ended		Sr	r. No.	Particulars			ended			
3 Months	Preceding 3	30/06/2013 in	Previous year				3 Months	Preceding 3	30/06/2013 in	Previous year		
ended	months ended	the previous	ended				ended	months ended	the previous	ended		
30/06/2014 (Unaudited)	31/03/2014 (Audited)	year (Unaudited)	31/03/2014 (Audited)	1			30/06/2014 (Unaudited)	31/03/2014 (Audited)	year (Unaudited)	31/03/2014 (Audited)		
(Unaudited)	(Auditeu)	(Orlaudited)	(Auditeu)	1		Income from operations	(Unaudited)	(Auditeu)	(Unaudited)	(Addited)		
205,680	195,198	164,633	720,834	1		Gross Sales	100,372	100,478	81,234	358,733		
3,642	3,565	3,888	14,827			Less: Excise Duty	1,681	1,436	1,532	6,280		
202,038	191,633	160,745	706,007	1		Net Sales	98,691	99,042	79,702	352,453		
2,974	5,217	2,960	16,396		a h	Other operating income	12,588	11,112	13,108	51,758		
	· · · · · ·	· · · · · ·		1	-	1 ' "						
205,012	196,850	163,705	722,403	2		Total income from operations (net)	111,279	110,154	92,810	404,211		
47.053	41.056	20.612	162.002			Expenses	24.555	26.672	24.064	100.014		
47,053	41,956	38,613 21,062	162,882 115,430		a	Cost of materials consumed Purchases of stock-in-trade	31,655	26,673	24,864 8,920	106,814		
40,624	33,620				b		11,537	10,580		38,266		
(6,345)	2,187	(5,736)			c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5,189)	32	(2,422)	(3,571)		
29,013	27,357	26,310	107,111			Employee benefits expense	15,176	13,303	13,409	52,514		
6,770	5,278	4,712	20,123		e	Depreciation and amortisation expense	5,295	3,217	3,039	12,740		
57,056	55,875	54,877	223,915	4	f	Other expenses	31,715	32,079	30,473	129,489		
174,171	166,273	139,838	622,512	١.	g	Total expenses	90,189	85,884	78,283	336,252		
30,841	30,577	23,867	99,891			Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)	21,090	24,270	14,527	67,959		
1,041	1,313	1,253	5,067	-		Other income	1,634	2,035	21,954	30,859		
31,882	31,890	25,120	104,958			Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	22,724	26,305	36,481	98,818		
1,808	2,404	2,784	9,019	-		Finance costs	825	1,001	1,460	4,251		
30,074	29,486	22,336	95,939			Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	21,899	25,304	35,021	94,567		
118	1,368	0	1,715			Exceptional items	0	0	0	0		
29,956	28,118	22,336	94,224			Profit/ (Loss) from ordinary activities before tax (7-8)	21,899	25,304	35,021	94,567		
5,244	3,476	2,031	10,601	10		Tax expense	2,170	3,636	999	4,208		
24,712	24,642	20,305	83,623			Net Profit/ (Loss) from ordinary activities after tax (9-10)	19,729	21,668	34,022	90,359		
0	0	0	0	-		Extraordinary items (net of tax expense)	0	0	0	0		
24,712	24,642	20,305	83,623			Net Profit/ (Loss) for the period (11-12)	19,729	21,668	34,022	90,359		
0	0	0	0	14		Share of profit/ (loss) of associates	0	0	0	0		
(691)	(723)	(799)	(3,264)	-		Minority interest	0	0	0	0		
24,021	23,919	19,506	80,359	16	5	Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	19,729	21,668	34,022	90,359		
10,237	10,237	10,237	10,237	17	7	Paid-up equity share capital (Face Value Rs. 5/-)	10,237	10,237	10,237	10,237		
			333,662	18	3	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				352,754		
				19) i	Earnings per share (before extraordinary items)						
						(of Rs. 5/- each) (not annualised):						
11.73	11.68	9.53	39.25	5	а	Basic (Rs.)	9.64	10.58	16.62	44.13		
11.73	11.68	9.53	39.25	5	b	Diluted (Rs.)	9.64	10.58	16.62	44.13		
					ii	Earnings per share (after extraordinary items)						
						(of Rs. 5/- each) (not annualised):						
11.73	11.68	9.53	39.25	5	а	Basic (Rs.)	9.64	10.58	16.62	44.13		
11.73						Diluted (Rs.)	9.64	10.58				
Notes I	11.00	7.55	33.23	1		I ()	7.01	10.50	13.02			

Notes

- [1] The above results for the quarter ended on June 30, 2014 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on July 30, 2014.
- The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per clause 41 of the Listing Agreement.
- [3] Effective from April 1, 2014, the Company has changed the depreciation charge based on the revised remaining useful lives of the assets as per the requirement of Schedule II of the Companies Act, 2013. Due to this, the depreciation charge for the quarter ended June 30, 2014 is higher by Rs. 1,613 Lacs on Standalone basis [Rs. 1,838 Lacs on Consolidated basis]. Further, based on

Act, 2013. Due to this, the deprecation charge for the quarter ended June 30, 2014 is higher by Rs. 1,613 Lacs on Standalone basis [Rs. 1,838 Lacs on Consolidated basis], runther, based on transitional provision provided in Note 7(b) of Schedule II, an amount of Rs. 2,497 Lacs on Standalone basis [Rs. 2,594 Lacs on Consolidated basis], which pertains to the carrying value of the assets whose remaining useful life as on April 1, 2014 is "Nil", has been adjusted to the Retained Earnings.

- The Company has incorporated Zydus Discovery DMCC as a wholly owned subsidiary in Dubai on June 15, 2014.
- [5] The changes in investments during the quarter are as under:
 - Zydus Worldwide DMCC [initial investments] Rs. 8 Lacs
 - Zydus Healthcare Philippines Inc. [additional investments] Rs. 26 Lacs
 - Zydus International Private Limited [additional investments] Rs. 4,633 Lacs
 - Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.
- [7] The Company has one segment of activity viz., "Pharmaceuticals".

PART II												
Select information for the Quarter Ended 30/06/2014												
3 Months	Preceding 3	Corresponding 3 months ended 30/06/2013 in	Previous year		Particulars	3 Months	Preceding 3	Corresponding 3 months ended 30/06/2013 in	Previous year			
ended	months ended	the previous	ended			ended	months ended	the previous	ended			
30/06/2014	31/03/2014	year	31/03/2014			30/06/2014	31/03/2014	year	31/03/2014			
				A 1	PARTICULARS OF SHAREHOLDING Public shareholding							
51,610,474	51,610,474	51,610,474	51,610,474		- Number of shares	51,610,474	51,610,474	51,610,474	51,610,474			
25.21%	25.21%	25.21%	25.21%		- Percentage of Shareholding	25.21%	25.21%	25.21%	25.21%			
				2	Promoters and Promoter Group Shareholding							
				а	Pledged / Encumbered							
Nil	Nil	Nil	Nil		- Number of shares	Nil	Nil	Nil	Nil			
N.A.	N.A.	N.A.	N.A.		- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	N.A.	N.A.	N.A.	N.A.			
N.A.	N.A.	N.A.	N.A.		- Percentage of shares (as a % of the total share capital of the company)	N.A.	N.A.	N.A.	N.A.			
				b	Non - encumbered							
153,138,046	153,138,046	153,138,046	153,138,046		- Number of shares	153,138,046	153,138,046	153,138,046	153,138,046			
100.00%	100.00%	100.00%	100.00%		- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100.00%	100.00%	100.00%	100.00%			
74.79%	74.79%	74.79%	74.79%		- Percentage of shares (as a % of the total share capital of the company)	74.79%	74.79%	74.79%	74.79%			
					Particulars	3 months ended 30/06/2014						
				В	INVESTOR COMPLAINTS [In Numbers]							

Pending at the beginning of the quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter

> By Order of the Board, For Cadila Healthcare Limited,

Pankaj R. Patel Chairman & Managing Director

Ahmedabad, July 30, 2014